FDA
-
-
-
-
-
-
-
Galera Therapeutics (GRTX) Announces Board Approval of Complete Liquidation and Dissolution
-
-
-
-
-
-
-
Galera Therapeutics (GRTX) says FDA reiterated need for additional Phase 3 trial of avasopasem manganese for radiotherapy-induced SOM
-
-
-
-
-
-
-
Galera Therapeutics (GRTX) Receives CRL from U.S. FDA for Avasopasem Manganese
-
-
-
-
-
-
-
Galera Expands Commercial Leadership Team
-
-
-
-
-
-
-
Galera Reports Fourth Quarter and Full Year 2022 Financial Results and Recent Corporate Updates
-
-
-
-
-
-
-
Galera Therapeutics (GRTX) Announces FDA Acceptance and Priority Review of Avasopasem NDA for Radiotherapy-Induced Severe Oral Mucositis
-
-
-
-
-
-
-
Galera Reports Third Quarter 2022 Financial Results and Recent Corporate Updates
-
323,573 total articles have been posted to this entity.
Click Here to Sign-Up for StreetInsider.com Premium to View All

